This clinical trial will evaluate the efficacy of Nefecon compared to matching placebo in patients with primary IgAN on a background of optimized RAS inhibitor therapy. Nefecon is a new oral formulation of budesonide that is designed to specifically deliver the drug to a place in the intestine where most of the immune cells producing IgA are located. Eligible participants will be randomly assigned to receive either 16 mg Nefecon or placebo. During Part A, participants will be asked to take their medication in the form of capsules to be swallowed by mouth once daily for 9 months. All participants included in the study will continue into Part B, which is an observational long-term follow up. During this time participants’ renal function will be followed. No investigational drug will be given during this period.
How To Contact a Study Center: